v3.25.2
Revenue (Tables)
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Product Reserve Accounts
The following table summarizes the balances and activity in each of the product reserve accounts for the six months ended June 30, 2025.
(in thousands)Rebates and DiscountsCo-Pay AssistanceProduct ReturnsTotal
Beginning balance at December 31, 2024$99 $29 $11 $139 
Provision related to revenue associated with sales processed in the six month period ended June 30, 2025252 55 30 337 
Adjustments related to revenue associated with sales processed in prior periods(16)6 — (10)
Credits and payments made during the period(94)(92)— (186)
Balance as of June 30, 2025$241 $(2)$41 $280 
Schedule of Accounts, Notes, Loans and Financing Receivable
The following table provides a rollforward of accounts receivable for the six months ended June 30, 2025.

(in thousands)Accounts Receivable
Beginning balance at December 31, 2024$1,070 
Increase in accounts receivable for drug product sales2,926 
Decrease in accounts receivable for cash collections(2,851)
Balance as of June 30, 2025$1,145 
Schedule of Allocation of Performance Obligation
The following table summarizes the allocation of transaction price to the three performance obligations in the Norgine Agreement based on the weighting of estimated stand-alone selling price for these performance obligations at the inception of the agreement.

Allocation of Transaction PriceRevenue Recognized
(in thousands)Six Months Ended June 30,
Performance Obligation:20252024
License$27,639 $27,639 $— 
Research and development services: WHIM312 25— 
Research and development services: CN 1,724 430— 
Total$29,675 $28,094 $—